<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl7" position="float"><object-id pub-id-type="doi">10.7554/eLife.08833.027</object-id><label>Table 7.</label><caption><p>Summary of oxidative stress protection by serotonin antagonists.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.08833.027">http://dx.doi.org/10.7554/eLife.08833.027</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Strain name</bold></th> <th>Fold change in survival after PQ [(Drug/DMSO) -1]<break/>Expt.1</th><th>Fold change in survival after PQ [(Drug/DMSO) -1]<break/>Expt.2</th><th>Fold change in survival after PQ [(Drug/DMSO) -1]<break/>Expt.3</th><th>Fold change in survival after PQ [(Drug/DMSO) -1]<break/>Expt.4</th><th>Fold change in survival after PQ [(Drug/DMSO) -1]<break/>Expt.5</th><th>Fold change in survival after PQ [(Drug/DMSO) -1]<break/>Expt.6</th><th>Fold change in survival after PQ [(Drug/DMSO) -1]<break/>Expt.7</th><th><bold>Mean,</bold> <break/><bold>Fold change in survival after PQ</bold></th> <th>S.D.,<break/>Fold change in survival after PQ</th><th><bold>P-value</bold></th> </tr></thead><tbody><tr><td colspan="11"><bold>Dihydroergotamine 88 &#181;M</bold></td> </tr><tr><td><bold>N2</bold></td> <td>0.62</td><td>0.70</td><td>0.79</td><td>0.19</td><td>1.75</td><td>1.43</td><td/><td><bold>0.91</bold></td> <td>0.57</td><td/></tr><tr><td><bold>ser-5(ok3087)</bold></td> <td>0.45</td><td>0.15</td><td/><td>0.10</td><td/><td/><td/><td><bold>0.23</bold></td> <td>0.19</td><td><bold>3.49E-02</bold></td> </tr><tr><td colspan="11"><bold>Metergoline 33 &#181;M</bold></td> </tr><tr><td><bold>N2</bold></td> <td>0.54</td><td>0.57</td><td>0.68</td><td>0.94</td><td>1.24</td><td>1.67</td><td/><td><bold>0.94</bold></td> <td>0.44</td><td/></tr><tr><td><bold>ser-5(ok3087)</bold></td> <td>-0.05</td><td>-0.27</td><td>-0.11</td><td/><td>-0.12</td><td/><td/><td><bold>-0.13</bold></td> <td>0.09</td><td><bold>1.50E-03</bold></td> </tr><tr><td colspan="11"><bold>Amperozide 13 &#181;M</bold></td> </tr><tr><td><bold>N2</bold></td> <td>0.93</td><td>0.74</td><td>0.99</td><td>0.92</td><td>2.49</td><td>0.89</td><td/><td><bold>1.16</bold></td> <td>0.66</td><td/></tr><tr><td><bold>ser-5(ok3087)</bold></td> <td>0.30</td><td>0.03</td><td/><td>-0.58</td><td/><td/><td/><td><bold>-0.09</bold></td> <td>0.45</td><td><bold>1.63E-02</bold></td> </tr><tr><td colspan="11"><bold>Methiothepin 10 &#181;M</bold></td> </tr><tr><td><bold>N2</bold></td> <td>0.80</td><td>1.08</td><td>0.95</td><td>0.36</td><td>0.77</td><td>2.94</td><td>1.39</td><td><bold>1.19</bold></td> <td>0.89</td><td/></tr><tr><td><bold>ser-5(ok3087)</bold></td> <td>0.07</td><td>0.10</td><td/><td>0.16</td><td>-0.01</td><td/><td/><td><bold>0.08</bold></td> <td>0.08</td><td><bold>1.24E-02</bold></td> </tr><tr><td colspan="11"><bold>Ketanserin 176 &#181;M</bold></td> </tr><tr><td><bold>N2</bold></td> <td>0.63</td><td>0.59</td><td>1.13</td><td>1.38</td><td>0.42</td><td>1.71</td><td/><td><bold>0.98</bold></td> <td>0.51</td><td/></tr><tr><td><bold>ser-5(ok3087)</bold></td> <td>-0.41</td><td>-0.14</td><td>0.01</td><td/><td>-0.07</td><td/><td/><td><bold>-0.15</bold></td> <td>0.18</td><td><bold>1.91E-03</bold></td> </tr><tr><td colspan="11"><bold>Mirtazapine 50 &#181;M</bold></td> </tr><tr><td><bold>N2</bold></td> <td>0.8</td><td>0.7</td><td>1.1</td><td>0.4</td><td>1.0</td><td>0.8</td><td>1.5</td><td><bold>0.89</bold></td> <td>0.35</td><td/></tr><tr><td><bold>ser-5(ok3087)</bold></td> <td>0.0</td><td>-0.1</td><td/><td>-0.1</td><td>-0.2</td><td/><td/><td><bold>-0.11</bold></td> <td>0.07</td><td><bold>1.92E-04</bold></td> </tr><tr><td colspan="11"><bold>LY-165,163 33/PAPP &#181;M</bold></td> </tr><tr><td><bold>N2</bold></td> <td>0.48</td><td>0.49</td><td>1.00</td><td>0.94</td><td>0.53</td><td>1.40</td><td/><td><bold>0.81</bold></td> <td>0.37</td><td/></tr><tr><td><bold>ser-5(ok3087)</bold></td> <td>-0.03</td><td>0.35</td><td>-0.07</td><td/><td>-0.16</td><td/><td/><td><bold>0.02</bold></td> <td>0.23</td><td><bold>3.19E-03</bold></td> </tr><tr><td colspan="11"><bold>Mianserin 50 &#181;M</bold></td> </tr><tr><td><bold>N2</bold></td> <td>1.10</td><td>1.11</td><td>1.18</td><td>0.53</td><td>3.24</td><td>1.60</td><td/><td><bold>1.46</bold></td> <td>0.94</td><td/></tr><tr><td><bold>ser-5(ok3087)</bold></td> <td>0.14</td><td>-0.18</td><td/><td>-0.26</td><td/><td/><td/><td><bold>-0.10</bold></td> <td>0.21</td><td><bold>4.49E-02</bold></td> </tr></tbody></table><table-wrap-foot><fn id="tblfn11"><p>Summary of all stress resistance assays performed in <xref ref-type="fig" rid="fig4s1">Figure 4&#8212;figure supplement 1b</xref>. The treatments, DMSO or serotonin antagonists, with their indicated concentrations (conc.) were added on day 1 of adulthood. Paraquat (PQ) (100 mM) was added on day 5 and survival after PQ [%] was calculated 24 hr later. Mean and standard deviation (S.D.) of survival after PQ [%] were calculated from 3 to 7 independent experiments (expts.). P-values were calculated between N2 and mutant strains for fold change values with indicated small molecule treatments using <italic>t-test</italic>.</p></fn></table-wrap-foot></table-wrap>